Biogen Inc. (BIIB) 当前追踪市盈率 (P/E) 为 20.2, 前瞻市盈率为 11.7. 追踪盈利收益率为 4.96%, 前瞻盈利收益率 8.58%. PEG 0.15 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $157.12.
本页证实的标准:
SharesGrow 综合评分： 60/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 16.7 | 1.63 | 5.10 | 5.41 | - |
| 2017 | 26.7 | -0.90 | 5.37 | 5.52 | - |
| 2018 | 13.9 | 0.17 | 4.73 | 4.58 | - |
| 2019 | 9.4 | 0.21 | 4.16 | 3.86 | - |
| 2020 | 9.8 | -0.47 | 3.68 | 2.93 | - |
| 2021 | 23.0 | -0.40 | 3.28 | 3.26 | - |
| 2022 | 13.2 | 0.13 | 3.00 | 3.96 | - |
| 2023 | 32.2 | -0.52 | 2.53 | 3.81 | - |
| 2024 | 13.7 | 0.34 | 1.33 | 2.30 | - |
| 2025 | 20.0 | -0.95 | 1.41 | 2.63 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $16.93 | $11.45B | $3.7B | 32.3% |
| 2017 | $11.92 | $12.27B | $2.54B | 20.7% |
| 2018 | $21.58 | $13.45B | $4.43B | 32.9% |
| 2019 | $31.42 | $14.38B | $5.89B | 41% |
| 2020 | $24.80 | $13.44B | $4B | 29.8% |
| 2021 | $10.40 | $10.98B | $1.56B | 14.2% |
| 2022 | $20.87 | $10.17B | $3.05B | 29.9% |
| 2023 | $7.97 | $9.84B | $1.16B | 11.8% |
| 2024 | $11.19 | $9.68B | $1.63B | 16.9% |
| 2025 | $8.83 | $9.81B | $1.29B | 13.2% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $15.76 | $13.55 – $17.28 | $9.43B | $9.27B – $10.05B | 20 |
| 2027 | $16.18 | $13.57 – $18.31 | $9.36B | $8.74B – $10.13B | 18 |
| 2028 | $17.34 | $16.37 – $19.08 | $9.47B | $9.46B – $9.49B | 6 |
| 2029 | $17.96 | $17.00 – $19.48 | $9.53B | $9.13B – $10.14B | 4 |
| 2030 | $18.14 | $17.17 – $19.67 | $9.6B | $9.21B – $10.23B | 2 |
